IBIO Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of 16.99%. iBio, Inc.'s return on equity of -80.97% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

iBio, Inc. has a consensus price target of $5.37, signalling upside risk potential of 171.04%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that iBio, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe iBio, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

iBio, Inc. has a beta of 1.357, which suggesting that the stock is 35.687% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. iBio, Inc.'s net income of -$9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 298.89x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of -5720% compared to iBio, Inc.'s net margin of 8.69%. iBio, Inc.'s return on equity of -80.97% beat Bristol Myers Squibb Co.'s return on equity of 39.9%.

iBio, Inc. has a consensus price target of $5.37, signalling upside risk potential of 171.04%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $62.72 which suggests that it could grow by 5.24%. Given that iBio, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe iBio, Inc. is more attractive than Bristol Myers Squibb Co..

iBio, Inc. has a beta of 1.357, which suggesting that the stock is 35.687% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.267, suggesting its less volatile than the S&P 500 by 73.293%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.34% to investors and pays a quarterly dividend of $0.63 per share. iBio, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 71.98% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

iBio, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.5B. iBio, Inc.'s net income of -$9M is lower than Bristol Myers Squibb Co.'s net income of $1.1B. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 16.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 298.89x versus 2.44x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of 18.15%. iBio, Inc.'s return on equity of -80.97% beat Merck & Co., Inc.'s return on equity of 36.76%.

iBio, Inc. has a consensus price target of $5.37, signalling upside risk potential of 171.04%. On the other hand Merck & Co., Inc. has an analysts' consensus of $128.59 which suggests that it could grow by 6.11%. Given that iBio, Inc. has higher upside potential than Merck & Co., Inc., analysts believe iBio, Inc. is more attractive than Merck & Co., Inc..

iBio, Inc. has a beta of 1.357, which suggesting that the stock is 35.687% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.446%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.85 per share. iBio, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

iBio, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. iBio, Inc.'s net income of -$9M is lower than Merck & Co., Inc.'s net income of $3B. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 298.89x versus 4.67x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -80.97% beat Savara, Inc.'s return on equity of -80.59%.

iBio, Inc. has a consensus price target of $5.37, signalling upside risk potential of 171.04%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that iBio, Inc. has higher upside potential than Savara, Inc., analysts believe iBio, Inc. is more attractive than Savara, Inc..

iBio, Inc. has a beta of 1.357, which suggesting that the stock is 35.687% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. iBio, Inc.'s net income of -$9M is higher than Savara, Inc.'s net income of -$32.2M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 298.89x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.